241. 高チロシン血症1型 Hypertyrosinemia type I Clinical trials / Disease details
臨床試験数 : 14 / 薬物数 : 7 - (DrugBank : 1) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 5
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2012-002286-36-DE (EUCTR) | 19/11/2012 | 03/08/2012 | Taste and palatability of Orfadin suspension. | Taste and palatability of Orfadin suspension. An open, non-controlled 3-day study in pediatric patients with hereditary tyrosinemia type 1 treated with Orfadin. | Hereditary tyrosinemia type 1 (HT-1) MedDRA version: 14.1;Level: LLT;Classification code 10069459;Term: Tyrosinaemia type I;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Product Name: Orfadin oral suspension 4mg/ml INN or Proposed INN: Nitisinone | Swedish Orphan Biovitrum AB | NULL | Not Recruiting | Female: yes Male: yes | 18 | Germany;United Kingdom | |||
2 | EUCTR2012-002286-36-GB (EUCTR) | 04/10/2012 | 10/08/2012 | Taste and palatability of Orfadin suspension. | Taste and palatability of Orfadin suspension. An open, non-controlled 3-day study in pediatric patients with hereditary tyrosinemia type 1 treated with Orfadin. | Hereditary tyrosinemia type 1 (HT-1) MedDRA version: 14.1;Level: LLT;Classification code 10069459;Term: Tyrosinaemia type I;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Product Name: Orfadin oral suspension 4mg/ml INN or Proposed INN: NITISINONE | Swedish Orphan Biovitrum AB | NULL | Not Recruiting | Female: yes Male: yes | 18 | Germany;United Kingdom |